Table 2.

Studies reporting statistics on a relation between baseline serum galactomannan and outcome.

References	Population	N	Parameter at baseline	Measured Outcome	p-value
Imbert et al., 2016a	SOT, hematological, solid tumor, ICU	40	sGM < 2.0	50% of day 90 survivors vs. 25% of day 90 non-survivors had sGM < 2.0 at baseline	0.19
Vehreschild et al., 2017c	Majority hematological	40	Mean sGM	0.9 in week 12 survivors vs. 4.3 in week 12 non-survivors	0.047
Jung et al., 2017a	SOT, hematological, AIDS, diabetes	102	sGM < 0.5	28% of day 30 survivors vs. 24% of day 30 non-survivors had sGM < 0.5 at baseline	0.81
			sGM < 0.5	51% of day 90 survivors vs. 41% of day 90 non-survivors had sGM < 0.5 at baseline	0.29
Neofytos et al., 2015	SOT, hematological, solid tumor	47	sGM < 0.5	OR 4.5 for good response at week 6	0.05
			sGM < 0.5	OR 7.0 for week 12 survival	0.02
López-Medrano et al., 2016	Kidney transplant recipients	112	Mean sGM	0.5 in week 6 survivors vs. 1.1 in week 6 non-survivors	0.024
			Mean BAL GM	1.0 in week 6 survivors vs. 6.5 in week 6 non-survivors	0.014
Heylen et al., 2015	Kidney transplant recipients	41	sGM	HR 1.371 for week 12 mortality	0.002
			BAL GM	HR 1.742 for week 12 mortality	0.243
Han et al., 2015	Pediatric hematological	45	Median sGM	0.46 in week 12 survivors vs. 1.21 in week 12 non-survivors	0.015
Teering et al., 2014a,d	Mixed ICU	44	Mean sGM	Correlated with hospital survival (exact statistic not reported)	NS
Russo et al., 2014	Hematological, solid tumor, COPD (all non-neutropenic)	27	Mean BAL GM	1.9 in week 6 survivors vs. 3.6 in week 6 non-survivors	0.02
Kim et al., 2014e	Hematological	391	sGM < 0.5	HR 2.28 for good outcome	0.026
Hoyo et al., 2014	SOT	24	sGM < 0.5	56% of day 30 survivors vs. 18% of day 3 non-survivors had sGM < 0.5 at baseline	0.021
Mikulska et al., 2013f	Allogeneic stem cell transplant recipients	57	sGM 0.5–0.99	HR 2.76 for day 42 mortality	NS
			sGM ≥ 2.0	HR 6.98 for day 42 mortality	NS
			sGM 0.5–0.99	HR 1.37 for day 180 mortality	NS
			sGM ≥ 2.0	HR 3.35 for day 180 mortality	NS
Fisher et al., 2013	Allogeneic stem cell transplant recipients	100	sGM ≥ 0.5	Adjusted HR 3.01 for week 6 respiratory mortality	0.038
			sGM ≥ 2.0	Adjusted HR 6.56 for week 6 respiratory mortality	0.003
			sGM ≥ 1.0	Adjusted HR 2.54 for day 180 respiratory mortality	0.024
			sGM ≥ 2.0	Adjusted HR 4.01 for day 180 respiratory mortality	0.003
			sGM < 1.0	Adjusted HR 2.12 for day 180 survival	0.024
			sGM < 2.0	Adjusted HR 4.08 for day 180 survival	0.002
Hadrich et al., 2012	Hematological	58	sGM	HR 1.044 for mortality	NS
Bergeron et al., 2012	Hematological	57	sGM	HR 1.25 for day 60 mortality	< 0.05
Koo et al., 2010	Hematological, SOT, solid tumor	93	sGM	Adjusted HR 1.25 for week 6 mortality	0.039
Boutboul et al., 2002b,g	Hematological	58	Mean sGM	Correlated with clinical response (exact statistic not reported)	NS

SOT, Solid organ transplantation; sGM, Serum galactomannan; OR, Odds ratio; HR, Hazard ratio; NS, Not significant;

^aModification of the 2008 EORTC-MSG classification criteria. N;

^bAuthor's own classification criteria;

^cOnly caspofungin treated patients;

^dAlso included possible cases;

^eOnly possible/probable cases, exclusion of patients with renal or hepatic failure. Outcome was a composite of 5 criteria;

^fOnly probable cases;

^gOutcome assessment after at least 7 days (not further specified).